TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04913493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytocam-IDF
Description: Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
Study: NCT06590987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strolll AR
Description: Strolll AR is an augmented-reality (AR) neurorehabilitation platform for delivering gait and balance exercises (assisted with cues when deemed beneficial) for Parkinson's disease onto state-of-the-art AR glasses.
Study: NCT04375566

Intervention type: OTHER
Intervention: Patient Decision Aid
Description: More than 20 IT specialists, 15 doctors and 15 patients

Intervention type: OTHER
Intervention: Patient Decision Aid
Description: More than 20 IT specialists, 15 doctors and 15 patients

Intervention type: OTHER
Intervention: Patient Decision Aid
Description: More than 20 IT specialists, 15 doctors and 15 patients
Study: NCT04886167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA
Description: Injection of platysmal bands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA
Description: Injection of platysmal bands.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA
Description: Injection of platysmal bands.
Study: NCT05628740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg NOC-100 (via nebulizer)
Description: Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 mg NOC-110 (via DPI) [1x 1 mg capsule]
Description: Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 mg NOC-110 (via DPI)
Description: Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (via DPI)
Description: Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6 mg NOC-110 (via DPI)
Description: Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6 mg NOC-110 (via DPI)
Description: Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (via DPI) [2x Placebo capsules]
Description: Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (via DPI) [2x Placebo capsules]
Description: Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
Study: NCT04790903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will self-administer Venetoclax, as described in the Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will self-administer Venetoclax, as described in the Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
Study: NCT04986059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-event massage
Description: Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
Study: NCT05337059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP and Tidal Volume Titration
Description: PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
Study: NCT04790903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
Study: NCT05117827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Wheelchair Standing Device
Description: A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
Study: NCT04113252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Possible Incentive for Tablet Return
Description: Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Possible Incentive for Tablet Return
Description: Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive for Completed Diary
Description: Subjects who return completed diary will receive a gift card.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive for Completed Diary
Description: Subjects who return completed diary will receive a gift card.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive for Completed Diary
Description: Subjects who return completed diary will receive a gift card.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Subjects will receive coaching prior to starting pain medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Subjects will receive coaching prior to starting pain medication.
Study: NCT05600400

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation
Description: 2 Fraction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Body Radiation
Description: 2 Fraction
Study: NCT05018845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05133648

Intervention type: PROCEDURE
Intervention: Hip Fracture Surgery
Description: Hip fracture surgery

Intervention type: PROCEDURE
Intervention: Hip Fracture Surgery
Description: Hip fracture surgery

Intervention type: PROCEDURE
Intervention: Hip Fracture Surgery
Description: Hip fracture surgery

Intervention type: OTHER
Intervention: COVID-19 infection
Description: COVID-19 infection
Study: NCT05251792

Intervention type: OTHER
Intervention: Ocular examination
Description: All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement

Intervention type: OTHER
Intervention: Ocular examination
Description: All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
Study: NCT05005000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micro-Fragmented Adipose Tissue (MFAT)
Description: 1ml of autologous micro-fragmented adipose tissue will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: The control group will receive a 1ml intraarticular injection of triamcinolone acetonide 10mg/ml.
Study: NCT05058274

Intervention type: DEVICE
Intervention: Implant of the AT-TORBI 709 lens
Description: Implant of the AT-TORBI 709 lens
Study: NCT05844826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMBA Capsule
Description: Participants will swallow capsule
Study: NCT05631756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
Study: NCT05627440

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Max Protein
Description: Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Original
Description: Ensure Original, 1 bottle daily (237 mL), 9 grams protein
Study: NCT05056246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maridebart cafraglutide
Description: Solution for injection
Study: NCT06082609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removable partial denture
Description: All patients will receive Removable partial denture by two different impression techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removable partial denture
Description: All patients will receive Removable partial denture by two different impression techniques
Study: NCT05980013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole blood donation supine
Description: Subjects will undergo a 1-unit whole blood donation in a supine position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole blood donation reclined
Description: Subjects will undergo a 1-unit whole blood donation in a reclined position
Study: NCT05427149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)
Description: It will be evaluated whether there is postpinal shivering in the cases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)
Description: It will be evaluated whether there is postpinal shivering in the cases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)
Description: It will be evaluated whether there is postpinal shivering in the cases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)
Description: It will be evaluated whether there is postpinal shivering in the cases.
Study: NCT05801978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Yellow Fever 17D Vaccine
Description: The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine
Description: The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
Study: NCT06309082

Intervention type: PROCEDURE
Intervention: Amputation
Description: Amputation was performed on diabetic foot ulcer

Intervention type: PROCEDURE
Intervention: Debridement
Description: Debridement of diabetic foot ulcers was performed
Study: NCT06250686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined exercise and nutrition intervention
Description: Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
Study: NCT05078723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limonene
Description: The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
Study: NCT05112263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: : Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
Study: NCT05325086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted information arm
Description: A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral information arm
Description: A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
Study: NCT04901117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin
Description: Use according to the drug combination options selected by each center.
Study: NCT04935931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone 50 mg PO x 1
Study: NCT04901117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan fumarate
Description: Use according to the drug combination options selected by each center.
Study: NCT05613634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercises
Description: Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey exercises
Description: Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
Study: NCT05310825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Wiping Bath with Single-Use Wipes
Description: Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Body Wiping Bath
Description: The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated